General Information
Drug ID
DR00654
Drug Name
Moxalactam
Synonyms
(6R,7R)-7-[[3-hydroxy-2-(4-hydroxyphenyl)-3-oxopropanoyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R-(6alpha,7alpha,7(S*)))-7-((Carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid; 1-Oxacephalosporin; 7b-[2-carboxy-2-(4-hydroxyphenyl)acetamido]-7a-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-1-oxa-1-dethia-3-cephem-4-carboxylic acid; 7beta-(2-Carboxy-2-(4-hydroxyphenyl)acetamido)-7alpha-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-1-oxa-1-dethia-3-cephem-4-carboxylic acid; Disodium Moxalactam; Festamoxin; LMOX; Lamoxactam; Latamoxef (INN); Latamoxef [INN:BAN]; Latamoxefum; Latamoxefum [INN-Latin]; Lilly 127935; Ly127935; Moxalactam; Oxa-cephem; S-6059; Sid 734787
Drug Type
Small molecular drug
Indication Bacterial infections [ICD11: 1A00-1H0Z] Approved [1]
Therapeutic Class
Antibiotics
Structure
3D MOL 2D MOL
Formula
C20H20N6O9S
Canonical SMILES
CN1C(=NN=N1)SCC2=C(N3C(C(C3=O)(NC(=O)C(C4=CC=C(C=C4)O)C(=O)O)OC)OC2)C(=O)O
InChI
InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1
InChIKey
JWCSIUVGFCSJCK-CAVRMKNVSA-N
CAS Number
CAS 64952-97-2
Pharmaceutical Properties Molecular Weight 520.5 Topological Polar Surface Area 232
Heavy Atom Count 36 Rotatable Bond Count 9
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 13
XLogP
-0.6
PubChem CID
47499
PubChem SID
103269737 , 104353085 , 11336084 , 11361323 , 11363865 , 11366427 , 11368989 , 11371639 , 11373726 , 11377151 , 11462295 , 11466847 , 11467967 , 11484790 , 11486374 , 11488883 , 11490326 , 11491879 , 11494785 , 117480923 , 117600506 , 124766432 , 126685470 , 128336018 , 134224607 , 134338426 , 134339083 , 135008052 , 135113257 , 137248766 , 137267739 , 14787236 , 15060840 , 34712479 , 46505546 , 47291366 , 47589221 , 48035393 , 48035394 , 48334770 , 48416297 , 49999588 , 57313109 , 625391 , 79526212 , 7980019 , 8180244 , 87299857 , 9440 , 96024799
ChEBI ID
CHEBI:599928
TTD Drug ID
D0O5LU
DT(s) Transporting This Drug PEPT2 Transporter Info Peptide transporter 2 Substrate [2]
References
1 Moxalactam was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.